Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Transcripts
    • AGM Invitations
    • IPOs
  • inderesTV
  • Forum
  • Discovery
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

Mendus Q4'23: New milestones

By Antti SiltanenAnalyst
Mendus

Last year was crucial for Mendus but the company managed to achieve important milestones during the year. Mendus CEO Erik Manting comments highlights of the Q4 and targets for this year in an interview with analyst Antti Siltanen.

Content:
00:00 Introduction
00:20 Mendus in a nutshell
02:33 Focused on maintenance therapy and measurable residual disease
06:27 Cellular immunotherapies
11:08 Safety profile and efficacy of vididencel
14:06 Milestones of 2023 and targets for 2024
17:14 Cash position

Stay up to date
Company management interviews

Recent videos

HCA Morgenbørs 14/04 - Markedet forsøger at løfte sig
14.04.2026, 09.25 Demant
Carasent, Audiocast, Q1'26
14.04.2026, 08.00 Carasent
Revenio’s press conference on the Visionix acquisition
13.04.2026, 13.00 Revenio Group
HCA Morgenbørs 13/04 - Ingen USA/Iran-aftale var nok ventet, men Trump's deadline er en presbold
13.04.2026, 10.28 ISS
HCA Morgenbørs 10/04 - Flade markeder og usikkerhed
10.04.2026, 09.42 Novo Nordisk
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.